IDEAYA Biosciences Inc
NASDAQ:IDYA
Income Statement
Earnings Waterfall
IDEAYA Biosciences Inc
Revenue
|
23.4m
USD
|
Operating Expenses
|
-157.8m
USD
|
Operating Income
|
-134.4m
USD
|
Other Expenses
|
21.5m
USD
|
Net Income
|
-113m
USD
|
Income Statement
IDEAYA Biosciences Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
9
N/A
|
20
+118%
|
27
+37%
|
36
+33%
|
36
+0%
|
28
-21%
|
32
+15%
|
29
-9%
|
50
+71%
|
51
+2%
|
47
-7%
|
45
-5%
|
23
-48%
|
23
0%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(36)
|
(40)
|
(44)
|
(42)
|
(44)
|
(47)
|
(48)
|
(50)
|
(55)
|
(59)
|
(66)
|
(73)
|
(78)
|
(87)
|
(96)
|
(104)
|
(113)
|
(122)
|
(130)
|
(142)
|
(158)
|
|
Selling, General & Administrative |
(5)
|
(6)
|
(7)
|
(9)
|
(10)
|
(11)
|
(13)
|
(14)
|
(15)
|
(17)
|
(17)
|
(19)
|
(20)
|
(21)
|
(22)
|
(23)
|
(24)
|
(24)
|
(26)
|
(27)
|
(28)
|
|
Research & Development |
(32)
|
(35)
|
(37)
|
(33)
|
(34)
|
(35)
|
(35)
|
(36)
|
(40)
|
(42)
|
(49)
|
(54)
|
(58)
|
(66)
|
(74)
|
(81)
|
(90)
|
(98)
|
(104)
|
(115)
|
(130)
|
|
Operating Income |
(36)
N/A
|
(40)
-11%
|
(44)
-9%
|
(42)
+5%
|
(44)
-5%
|
(47)
-5%
|
(48)
-3%
|
(41)
+14%
|
(35)
+15%
|
(32)
+9%
|
(30)
+5%
|
(37)
-22%
|
(50)
-35%
|
(55)
-10%
|
(67)
-21%
|
(54)
+19%
|
(63)
-15%
|
(75)
-19%
|
(85)
-14%
|
(119)
-40%
|
(134)
-13%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
2
|
2
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
2
|
4
|
6
|
11
|
16
|
21
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(34)
N/A
|
(38)
-11%
|
(42)
-10%
|
(40)
+5%
|
(42)
-6%
|
(44)
-6%
|
(46)
-4%
|
(40)
+13%
|
(35)
+14%
|
(31)
+9%
|
(30)
+5%
|
(37)
-22%
|
(50)
-36%
|
(55)
-10%
|
(66)
-20%
|
(53)
+20%
|
(59)
-11%
|
(68)
-16%
|
(74)
-9%
|
(103)
-39%
|
(113)
-9%
|
|
Net Income | ||||||||||||||||||||||
Income from Continuing Operations |
(34)
|
(38)
|
(42)
|
(40)
|
(42)
|
(44)
|
(46)
|
(40)
|
(35)
|
(31)
|
(30)
|
(37)
|
(50)
|
(55)
|
(66)
|
(53)
|
(59)
|
(68)
|
(74)
|
(103)
|
(113)
|
|
Net Income (Common) |
(34)
N/A
|
(38)
-11%
|
(42)
-10%
|
(40)
+5%
|
(42)
-6%
|
(44)
-6%
|
(46)
-4%
|
(40)
+13%
|
(35)
+14%
|
(31)
+9%
|
(30)
+5%
|
(37)
-22%
|
(50)
-36%
|
(55)
-10%
|
(66)
-20%
|
(53)
+20%
|
(59)
-11%
|
(68)
-16%
|
(74)
-9%
|
(103)
-39%
|
(113)
-9%
|
|
EPS (Diluted) |
-1.76
N/A
|
-1.96
-11%
|
-2.06
-5%
|
-1.97
+4%
|
-3.36
-71%
|
-2.19
+35%
|
-2.19
N/A
|
-1.41
+36%
|
-1.4
+1%
|
-0.99
+29%
|
-0.91
+8%
|
-0.97
-7%
|
-1.41
-45%
|
-1.41
N/A
|
-1.71
-21%
|
-1.28
+25%
|
-1.42
-11%
|
-1.41
+1%
|
-1.31
+7%
|
-1.72
-31%
|
-1.96
-14%
|